Replies to post #16078 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

MNTA continues to have very strong liquidity:

While the liquidity is nice and safe the way they built that equity was by issuing greater than 30% in new shares over the last two years. Those extra 20 million shares have created a new "normal" channel represented by the lower stock price.

The $6 in cash per share certainly isn't represented in the $11 stock price.

[DewDiligence]

MNTA’s 12/31/16 pro forma cash balance was $485.6M—an increase of $110.3M relative to the pro forma cash balance on 9/30/16:

https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta1231201610k.htm#s8E0293C0D7E45268AB8DFF4D3C3CC319

The $485.6M pro forma cash consists of: $353.2M of unrestricted cash and marketable securities; $37.3M of net collaboration receivables from MYL relating to the companies’ FoB partnership; $21.8M of restricted cash (mostly relating to the Lovenox patent case); $51.2M received from SHPG in Jan 2017 pursuant to the termination of the M923 partnership (#msg-127579499); the $50.0M up-front amount payable by CSL for the autoimmune collaboration announced in Jan 2017 (#msg-127656306); less $27.9M in net accounts payable and deferred expenses.